Stocktoria
Janux Therapeutics, Inc. JANX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-06-11
Chart by TradingView
2/9
Piotroski F — financial health
26.48
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $10.0M | $10.6M | $8.1M | $8.6M | $3.6M |
| Operating income | -$157.7M | -$98.8M | -$73.0M | -$67.1M | -$32.9M |
| Net income | -$113.6M | -$69.0M | -$58.3M | -$63.1M | -$32.7M |
| Operating cash flow | -$82.2M | -$43.8M | -$50.6M | -$42.9M | -$17.0M |
| Free cash flow | -$83.3M | -$44.2M | -$52.4M | -$49.4M | -$18.5M |
| Total assets | $1.0B | $1.1B | $380.4M | $364.0M | $379.8M |
| Total liabilities | $44.7M | $38.7M | $36.1M | $43.3M | $13.5M |
| Shareholders' equity | $956.8M | $1.0B | $344.3M | $320.7M | $366.3M |
| Ratios | |||||
| Operating margin | -1576.7% | -933.6% | -902.9% | -779.0% | -905.4% |
| Net margin | -1136.2% | -651.6% | -721.2% | -732.2% | -898.3% |
| FCF margin | -832.8% | -417.2% | -648.6% | -573.2% | -507.5% |
| Return on assets | -11.3% | -6.5% | -15.3% | -17.3% | -8.6% |
| Return on equity | -11.9% | -6.7% | -16.9% | -19.7% | -8.9% |
| Current ratio | 39.04 | 59.21 | 26.80 | 20.14 | 29.46 |
| Revenue growth | -5.6% | 31.0% | -6.1% | 136.8% | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 1,156,140 | $16.1M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 26.48 (safe)
- Working capital / assets 0.949
- Retained earnings / assets -0.351
- EBIT / assets -0.157
- Equity / liabilities 21.385
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001817713 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.